# Synthesis of Purine-1,4,7,10-Tetraazacyclododecane Conjugate and Its Complexation Modes with Copper(II)

Aleksejs Burcevs, Gediminas Jonusauskas, Irina Novosjolova, Māris Turks

► To cite this version:

Aleksejs Burcevs, Gediminas Jonusauskas, Irina Novosjolova, Māris Turks. Synthesis of Purine-1,4,7,10-Tetraazacyclododecane Conjugate and Its Complexation Modes with Copper(II). Molecules, 2025, 30 (7), pp.1612. 10.3390/molecules30071612. [hal-05022700](https://hal.science/hal-05022700v1)

HAL Id: hal-05022700

https://hal.science/hal-05022700v1

Submitted on 7 Apr 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Article

# Synthesis of Purine-1,4,7,10-Tetraazacyclododecane Conjugate and Its Complexation Modes with Copper(II)

Aleksejs Burcevs <fnref n="1" /> ID, Gediminas Jonusauskas <fnref n="2" /> ID, Irina Novosjolova <fnref n="1" />,* ID and Māris Turks <fnref n="1" />,* ID

**Abstract:** Purine-1,4,7,10-tetraazacyclododecane (cyclen) conjugate was designed to study its Cu<fnref n="2" />⁺ ions complexation capability. Several synthetic approaches were tested to achieve the target compound. The optimal approach involved stepwise modifications of purine N9, C8, and C6 positions that, in nine consecutive steps, provided purine-cyclen conjugate. The synthetic sequence involved Mitsunobu-type alkylation at N9 and iodination at C8, followed by Stille, S<sub>N</sub>Ar, CuAAC, and alkylation reactions. The designed purine-cyclen conjugate is able to complex Cu<fnref n="2" />⁺ ions in both the cyclen part and between the purine N7 and triazole N2 positions. The complexation pattern and equilibrium were studied using the NMR titration technique in MeCN-d<sub>3</sub> and absorption spectra.

**Keywords:** purines; fluorescence; metal ion complexation; synthesis; cyclen

## 1. Introduction

Purines have a broad range of applications in medicine and materials science due to their wide biological [1–4] and photophysical [5–12] properties. Therefore, the importance of the development of new synthetic approaches towards intended substitution into purine is high.

In this study, we designed purine-cyclen conjugate **1** as a potential photocatalyst (Figure 1). The incorporation of redox-active transition metals into organic light-absorbing molecular structures makes it possible to use light to change the oxidation state of metal ions. Cyclen derivative is an attractive moiety for derivatization due to its great ability to complex such metal ions as Cu<fnref n="2" />⁺, Ni<fnref n="2" />⁺, Pd<fnref n="2" />⁺, and Zn<fnref n="2" />⁺ [13–18]. The photoinitiated electron transfer may be easily controlled and directed toward a site containing metal ions. Moreover, the use of available molecular building blocks using well-developed synthetic methods makes the molecular construction easily adapted for specific metal ions and targeted chemical reactions. The ON/OFF switching possibility of the catalytically active state largely increases the flexibility in the control of the reaction.

Our previous work [19] inspired us to create a new structural design of the photocatalyst based on the purine core. Instead of using benzophenone with its complicated excited state behavior, including unwanted side reactions, the ground state association between dimethylaniline electron donor and strongly absorbing antenna, bearing purine, will ensure efficient light absorption and electron transfer between them without wasting the absorbed energy. The oxidation potentials of all molecular fragments are known to be optimal for an electron transfer until copper(II) is bound by cyclen. The formed copper(I) may be used for a wealth of chemical reactions, including the generation of H₂O₂, which possesses

<figure><img src="image_2.png" /></figure>

check for
updates

Academic Editor: Gianfranco Favi

Received: 3 March 2025

Revised: 21 March 2025

Accepted: 2 April 2025

Published: 4 April 2025

**Citation:** Burcevs, A.; Jonusauskas, G.; Novosjolova, I.; Turks, M. Synthesis of Purine-1,4,7,10-Tetraazacyclododecane Conjugate and Its Complexation Modes with Copper(II). *Molecules* **2025**, *30*, 1612.
https://doi.org/10.3390/molecules30071612

**Copyright:** © 2025 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

<footnote n="1">¹ Institute of Chemistry and Chemical Technology, Faculty of Natural Sciences and Technology, Riga Technical University, P. Valdena Str. 3, LV-1048 Riga, Latvia</footnote>

<footnote n="2">² Laboratoire Ondes et Matière d'Aquitaine, Bordeaux University, UMR CNRS 5798, 351 Cours de la Libération, 33405 Talence, France</footnote>

<footnote>* Correspondence: irina.novosjolova@rtu.lv (I.N.); maris.turks@rtu.lv (M.T.)</footnote>
high reactivity towards biological structures and may also be employed for wastewater
treatment using only sunlight.

<figure><img src="image_3.png" /><figcaption>**Figure 1.** The structure of purine–cyclen conjugate 1 as a potential photocatalyst.</figcaption></figure>

Over the years, a wide range of methods for the derivatization of purines have been
developed. Four positions in the purine core can be modified: C2, C6, C8, and N7 or N9.
Derivatization of the C positions of the purine cycle is usually done in metal-catalyzed
cross-coupling or S<sub>N</sub>Ar reactions (Scheme 1). In S<sub>N</sub>Ar reactions, halogens are the most
common leaving groups in the purine, but there are reports about sulfonyl groups [20],
azides [21], and C-N bonded 1,2,3-triazoles [22] acting as leaving groups as well. Various
O- [23,24], N- [25–27], and S- [20,23,28] nucleophiles have been introduced to the purine
ring via S<sub>N</sub>Ar reactions. On the other hand, the most widespread cross-coupling reactions
within the purine core are Suzuki-Miyaura [29–31], Negishi [32,33], Stille [34,35], and
Sonogashira [36–38] reactions. In cases of di- or trihalogenated purines, reactions occur
chemo- and regioselectively [39,40], with the purine C6 position being the most reactive. By
choosing different halogens at the purine core, it is possible to control reaction occurrence
at less reactive positions with the introduction of the iodine there. It is worth noting that
the proton at the purine C8 position is the most acidic, making it the primary target of
deprotonation and C-H activation reactions [41–43].

<figure><img src="image_4.png" /><figcaption>**Scheme 1.** Most used approaches for derivatization of purine at C2, C6, C8, N7, and N9 positions.</figcaption></figure>

In derivatizations of the *N*9 position of purine, a mixture of products is frequently
formed due to the purine imidazole ring *N*7/*N*9 position tautomerism. The most used reac-
tions for the introduction of the substituents to the *N*9 position are alkylation, Mitsunobu,
and copper-catalyzed cross-coupling reactions [41,42,44]. Alkylation reactions with the for-
mation of *N*7 product as a major product are challenging, requiring specific substrates and
additives, like alkyl halides in the presence of Grignard reagents [45], glycosyl donors or *tert*-butyl halides with bis(trimethylsilyl)acetamide, TiCl₄ or SnCl₄ [46,47]. The most certain way of acquiring *N*7 purine derivatives is purine de novo synthesis from the corresponding pyrimidines [48] or imidazoles [49].

In addition, purine derivatives can complex metal ions and be used in medicine and as metal ion sensors. Cisplatin (cis-diamminedichloroplatinum(II)) is a known anticancer drug where the metal binds with the *N*7-positions of guanine bases and thus activates signal transduction pathways and apoptosis [50]. In 1971, 6-amino-, 6-chloro-, 6-hydroxy- and 6-mercaptopurines were studied for such metals as Mn²⁺, Ca²⁺, Mg²⁺, Zn²⁺, Ni²⁺, Co²⁺, and Cu²⁺ complexation in water, and it was proposed that the 1:1 complexes formed and metal coordinated to *N*7 of purine and to substituent at C6 position [51].

Purine-metal complexes are often studied by fluorescence because, due to the formation of complexes, fluorescence changes. Known purine-based derivatives are used as sensors for Hg²⁺ and Pd²⁺ ion detection in aqueous media [52,53] and for Cu²⁺ in cells [54,55]; upon complexation, they quench the fluorescence. Recently, there were published reports about purine nucleoside complexes for Cu²⁺ ions [56,57]. On the other hand, purine Schiff base conjugate forms complexes with Al³⁺ and increases the fluorescence [58]. 1,2,3-Triazolyl pyridine, isoquinoline, and ferrocene derivatives form complexes with Pd²⁺, Cu²⁺, Ni²⁺, Ru²⁺, Au⁺, and Ag⁺, but there is only one example in the literature of 2,6-bistriazolylpurine derivatives, which can serve as ratiometric fluorescence cation sensors, especially for the Zn²⁺ and Ca²⁺ ions [59].

The formation constant for tetramethylated cyclen and Cu²⁺ complex reaches logK 18.4 [60]. For triazole-pyridine-triazole conjugate with tridentate coordination of Cu²⁺ ions complex with logK 19.69 forms, and the complex is protonated (logβ[CuHL₂]³⁺ [61]. On the other hand, 6-aminopurine forms a complex with Cu²⁺ ions with coordination to the *N*7 position and amino group at the C6 position and a formation constant logK 8.94 [62]. 3-Methyl-5-pyridin-2-yl-1,2,4-triazole forms complexes with Cu²⁺ ions in metal-to-ligand ratios 1:1 and 1:3, and their complex formation logK are 10.35 and 17.82, respectively [63]. Based on this information, the competitive complexation between cyclen moiety Cu²⁺ ions and between the *N*7 position of purine and the *N*2 position of triazole and Cu²⁺ ions may take place. In addition, the most structurally related compounds to the target compound **1** reported in the literature are purine-copper-cyclen complexes, where purine and cyclen moieties are separate ligands and are not linked within a single molecule. In these complexes, copper ions coordinate with the nitrogen atoms of the cyclen and purine *N*7, *N*9, or *N*3 positions. However, binding constants for these interactions have not been reported. Notably, these studies are focused on the chelating properties of the complexes rather than their potential photocatalytic applications [64,65].

Hence, we report here the design and synthesis of the purine derivative, which contains all the foreseen necessary substituents for metal complexation along with light absorption and electron transfer from the organic ligand to the metal center.

## 2. Results and Discussion

The proposed structure consists of a purine core and three main moieties A, B, and C, which may be added in various order. The retrosynthetic analysis of the proposed structure **1** offers possible approaches toward the introduction of target building blocks (Scheme 2). Moiety A makes it possible to construct via copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) between the azido group containing purine derivative **2** and alkyne **3**. Thus, the azidation of 6-chloropurines is well-known and results in high to quantitative yields [66,67], while corresponding alkyne **3** requires a separate synthetic approach. Derivatization of the purine C8 position is possible to achieve via a palladium-
catalyzed cross-coupling reaction. We decided to use the Stille reaction conditions due to the easy, one-step synthesis of the stannane 5 from commercially available 4-bromo-N,N-dimethylaniline [68]. The introduction of moiety C is proposed to be achieved in two ways—either via the Mitsunobu reaction between 9H-purine 6 and cyclen derivative 7 or using the S<sub>N</sub>2 reaction between substituted 9-(2-iodoethyl)-9H-purine 8 and cyclen derivative 9.

<figure><img src="image_5.png" /><figcaption>**Scheme 2.** Retrosynthetic analysis toward purine-cyclen conjugate 1.</figcaption></figure>

In general, we have explored several synthetic routes toward target compound **1**. The first synthetic route started with S<sub>N</sub>Ar reaction between 6-chloro-9-tetrahydropyranyl purine **10** [69] and sodium azide, resulting in 6-azidopurine derivative **11** in a 70% yield (Scheme 3). Next, we envisioned two approaches for the construction of moiety A at the C6 position of purine. The first approach included the CuAAC reaction of compound **11** with 2-(prop-2-yn-1-yloxy)ethan-1-ol (12) [70], followed by the derivatization of the free hydroxyl group of an obtained product **13**. While the CuAAC reaction successfully provided triazole derivative **13** in a 63% yield, the further derivatizations with 4-bromo-N,N-dimethylaniline (14) via copper-catalyzed Ullmann-type reactions were unsuccessful [71–73]. For this transformation, we applied previously reported reagent systems of KOH/CuI/1,10-phenanthroline/*n*-Bu<sub>4</sub>NI at 100 °C [71], CuI/3,4,7,8-tetramethyl-1,10-
phenanthroline/Cs₂CO₃ at 110 °C [72] and CuI/K₃PO₄/8-hydroxyquinoline at 110 °C [73], but did not achieve any conversion. For the second approach, building block **3** was obtained in 4 steps from 1-bromo-4-nitrobenzene (16) and used in CuAAC reaction with compound **11**, resulting in a 56% yield of desired product **15**. While deprotection of the tetrahydropyranyl group at the purine N9 position of compound **15** was easily achieved in AcOH/H₂O/THF mixture at 50 °C temperature overnight, further attempts to derivatize N9 position of this compound using the Mitsunobu (DIAD/PPh₃/2-bromoethanol or 2-chloroethanol at 0 → 60 °C) or alkylation (NaH/1,2-dibromoethane at 0 → 100 °C) reaction procedures were not fruitful. The explanation involves the electron-poor nature of the purine system and the reduced reactivity of the N9 position after the introduction of the triazolyl moiety A. This encouraged us to design the second approach toward the desired compound **1**.

<figure><img src="image_6.png" /><figcaption>**Scheme 3.** Attempts to introduce moiety A to the 6-chloro-9-tetrahydropyranyl purine **10**.</figcaption></figure>

Next, we decided to introduce the THP-protected oxyethyl linker at the N9 position prior to derivatization of the C6 position with moiety A, keeping in mind that the cyclen part should be introduced later due to the excellent complexation ability of cyclen with transition metals [16], which would make CuAAC and cross-coupling reactions impossible. Thereby, the second synthetic route started with a Mitsunobu reaction between 6-chloropurine (20) and 2-(cyclohexyloxy)ethan-1-ol (21) [74], yielding product 22 in a 60% yield (Scheme 4). Next, the sequence of S<sub>N</sub>Ar and CuAAC reactions was used toward compound 24. The following bromination attempt of the C8 purine position with NBS resulted in phenyl ring bromination instead, providing product 25 with a 59% yield. The use of LDA and other deprotonation reagents (NaH and *n*-BuLi) led to the deprotonation of triazole instead of
the purine C8 position, so we concluded that the introduction of halogen to the C8 position and moiety B should be done prior to the derivatization of the C6 position.

<figure><img src="image_7.png" /><figcaption>**Scheme 4.** Introduction of THP-protected oxyethyl linker to 6-chloropurine (20), followed by a moiety A and attempts to modify the C8 purine position.</figcaption></figure>

The final synthetic route started with the iodination of previously obtained compound **22** using the LDA and $I_2$ reagent system (Scheme 5). After that, a Stille cross-coupling reaction between $N,N$-dimethyl-4-(tributylstannyl)aniline (5) and purine derivative **26** resulted in C8 derivatized product **27** in a 52% yield. Next, the $S_N$Ar and CuAAC reaction sequence was performed to achieve compound **29**. Further, THP group cleavage with the following mesylation step resulted in almost quantitative yields in both transformations. In the first attempts, cyclen derivative **9**, which was previously obtained in three steps using literature methods [75], did not react with acquired mesylate **31** in the $S_N$2 reaction. Thus, we decided to substitute the mesylate group with bromide and then perform an alkylation reaction with cyclen derivative **9**. The best conversion toward target product **1** in this reaction was 20%, with a 6% isolated yield due to the difficulties with purification stemming from the similar polarity of by-products. In addition, this transformation preferred the E2 mechanism, forming elimination product **32** as a main by-product with 57% isolated yield.

With target product **1** in hand, we did preliminary studies using ¹H NMR titration experiments (in the Supplementary Materials) to determine the complexation ability of purine-cyclen conjugate toward metal ions. Purine-cyclen conjugate **1** was titrated in MeCN-$d_3$ with Cu²⁺ ions using Cu(ClO₄)₂·6H₂O as a Cu²⁺ source and benzene as an internal standard. The corresponding spectra were taken after each 0.1 eq. addition of Cu²⁺ ions (Figure 2).

The shifts of the signals correspond to protons from triazole at the C6 position of purine, phenyl ring at the C8 position of purine, and cyclen at the N9 position of purine. The ¹H NMR spectra show relatively complex behavior of the Cu²⁺ binding process by compound **1**. The most important feature representing an expected Cu²⁺ binding in cyclen is shown by a thick arrow at the values 2.0–2.5 ppm. Starting from approximately 0.7 equivalents of metal ion, all ¹H NMR signals of cyclen assemble into a single peak at approximately 2.2 ppm, which does not shift at higher concentrations of Cu²⁺. This fact indicates that metal ion is coordinated inside the cyclen ring in a unique configuration, and all four
cyclen nitrogens are equally involved in metal ion binding. An additional metal binding site between triazole and purine nitrogens is also occupied by Cu²⁺, as is seen by triazole proton shift at approximately 9.0–9.2 ppm. The proton shifts of the other aromatic fragments of compound **1** indicate the rearrangements of electron density over the molecule during the complexation process. Based on NMR titration experiments, the possible equivalence points were determined at 0.35 and 0.50 equivalents, which corresponded to M1:L3 and M1:L2 complexes, respectively (Figures **3** and **4**). The competitive complexation happened between the cyclen part and the triazole *N*2 and purine *N*7 positions.

<figure><img src="image_8.png" /><figcaption>**Scheme 5.** The final synthetic route toward target purine-cyclen conjugate **1**.</figcaption></figure>

Due to the paramagnetic nature of the copper, the performance and analysis of NMR experiments and obtaining spectra at higher metal ion concentrations turn out to be difficult. Thus, the complex formation of compound **1** with Cu²⁺ and the UV-spectrophotometric titration was performed in acetonitrile (ACN) at room temperature, and it confirmed the result obtained by ¹H NMR titration. The initial concentration of **1** was 5 × 10⁻⁵ mol/L.
The ratio of compound **1** to Cu²⁺ was varied by adding aliquots of a solution of copper(II) perchlorate with 0.125 × 10⁻⁶ mol/L concentration.

<figure><img src="image_9.png" /><figcaption>**Figure 2.** ¹H NMR titration spectra of compound **1** with Cu²⁺ ions in MeCN-d₃.</figcaption></figure>

<figure><img src="image_10.png" /><figcaption>**Figure 3.** The change of the chemical shifts of Ar₁ and cyclen proton signals in ¹H NMR titration experiments for compound **1** with Cu²⁺ ions in MeCN-d₃.</figcaption></figure>
<figure><img src="image_11.png" /><figcaption>**Figure 4.** Possible Cu²⁺ complexes with purine–cyclen conjugate.</figcaption></figure>

The variation of absorption spectra upon adding Cu²⁺ into the solution of **1** is quite complex, yet the step-by-step analysis of absorption spectra crossed with the data of NMR titration provides a realistic picture of the composition and geometry of the formed complexes (Figures 4–6). The increase of the intensity of spectral feature at approximately 290 nm indicates the increase of the concentration of Cu²⁺ ions in the ACN solution. According to the literature [76], this absorption band may be attributed to the ligand-to-metal charge transfer (LMCT) transition between ACN and copper ion. At the concentrations corresponding to metal–ligand ratio below 1:1, the main spectral changes occur at the 450–800 nm spectral range (Figure 5a). The absorption bands observed may be attributed to the d-d transition of Cu²⁺ ions coordinated by cyclen nitrogens [15].

It is important to note that the main absorption band (including the vibronic replicas) located at 370 nm remains at the same position; only the intensity varies within 30% (Figure 5b). Such behavior may suggest that the π-conjugated electronic system of N,N-dimethylaniline-purine fragment is not affected by a metal ion. The main coordination site for Cu²⁺ is located inside cyclen until the metal–ligand ratio reaches 1:1; the ligands in excess are most probably oriented with triazole-purine fragment pointing towards Cu²⁺ inside cyclen and forming a lossy 1:3 and 1:2 complexes. After the metal–ligand ratio exceeds 1:1, the 370 nm absorption band starts to decay, causing a simultaneous rise of a new absorption band at 410 nm, which reaches its maximum at a metal–ligand ratio equal to 2:1. The formation of a new red-shifted absorption band is a typical spectroscopic signature of coordination of metal ion by an acceptor in donor-acceptor compounds; in
our situation, it corresponds to the coordination of the second Cu²⁺ by triazole-purine fragment. Additionally, selected absorption spectra, together with complex compositions and supposed geometries, as well as types of vertical transitions involved [76], are presented in Figure 6.

<figure><img src="image_12.png" /><figcaption>**Figure 5.** (a) The variation of the absorption spectra of complexes going from pure compound **1** until a 1:1 metal–ligand ratio; (b) the absorption spectra of complexes with compositions going from 1:1 until a 2:1 metal–ligand ratio.</figcaption></figure>

<figure><img src="image_13.png" /><figcaption>**Figure 6.** Characteristic absorption spectra extracted from spectrophotometric titration experiment indicating types of vertical transitions, compound **1**: Cu²⁺ complex compositions, and supposed geometries.</figcaption></figure>
# 3. Materials and Methods

## 3.1. General Information

Compounds **5, 9, 10, 12**, and **21** were prepared according to the procedures outlined in the literature [68–70,74,75]. Compounds **17–19** were prepared using synthetic procedures described in this work, and their ¹H spectra match the literature [77–79].

Commercial grade reagents and solvents were purchased from Sigma-Aldrich (Burlington, MA, USA), Fluorochem (Hadfield, UK) or BLD Pharm (Reinbek, Germany) at the highest commercial quality and used without further purification.

The absorption spectra were recorded using the UV-VIS-NIR absorption spectrometer Varian Cary 5000 (Agilent Technologies, Santa Clara, CA, USA). Overall, more than 200 titration steps were provided to obtain the full picture of the complexation process.

## 3.2. Characterization Data for Products

### 3.2.1. 2-(4-Nitrophenoxy)ethan-1-ol (17)

KOH (26.7 g, 0.48 mol, 4.0 eq.) was added in portions to abs. ethylene glycol (200 mL) at 0 °C, and the solution was stirred for 30 min at 0 °C. Then, the reaction mixture was warmed up to 25 °C and stirred until KOH was fully dissolved. Meanwhile, 1-bromo-4-nitrobenzene (16) (24.0 g, 0.12 mol, 1.0 eq.) was dissolved in abs. DMSO (200 mL) was then added to the KOH solution and stirred at 50 °C for 30 min. An additional abs. DMSO (40 mL) was added until everything was dissolved, and the reaction was stirred overnight at 50 °C for 16 h. The final reaction mixture was poured into cold water (1.5 L), and the formed precipitate was filtered (13.53 g of 17). Filtrate was extracted with DCM (3 × 100 mL). The organic phase was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, evaporated in a vacuum, and then lyophilized from the remaining DMSO. After lyophilization, the solid was dissolved in a minimum amount of DCM, added to the cold hexane (100 mL), and the resulting precipitate was filtered (6.4 g of 17). Beige amorphous solid, yield: 19.93 g, 92%. ¹H-NMR spectrum is consistent with the literature [77].

### 3.2.2. 2-(4-Aminophenoxy)ethan-1-ol (18)

Compound **17** (13.5 g, 73.77 mmol, 1.0 eq.) and 10% palladium on carbon (1.35 g) were suspended in MeOH (300 mL) and H₂ gas was bubbled through for 6 h at 25 °C. The reaction was controlled with HPLC. The reaction mixture was filtered through a celite pad and evaporated, providing product **18** (yield: 11.12 g, 99%) as a brown oil. HPLC: t<sub>R</sub> = 1.47 min, eluent E₁. ¹H-NMR spectrum is consistent with the literature [78].

### 3.2.3. 2-(4-(Dimethylamino)phenoxy)ethan-1-ol (19)

Compound **18** (11.12 g, 72.7 mmol, 1.0 eq.) and NaBH₄ (16.5 g, 436.2 mmol, 6.0 eq.) were suspended in abs. THF (250 mL) and then slowly added to the mixture of H₂SO₄ (3M, 28.8 mL) and H₂CO (37%, 21.6 mL) at 0 °C. The resulting mixture was left to stir for 2 h at 25 °C, then 4 h at 50 °C. The reaction mixture was basified with 2M KOH solution till pH = 11 and extracted with DCM (2 × 100 mL). The organic phase was washed with brine (2 × 100 mL), dried over anhydrous Na₂SO₄, filtered and evaporated. Silica gel column chromatography (EtOH/Tol, gradient 0% → 7%) provided product **19** (yield: 9.16 g, 70%) as a brown amorphous solid. R<sub>f</sub> = 0.73 (Tol/EtOH = 5:1). ¹H-NMR spectrum is consistent with the literature [79].

### 3.2.4. N,N-Dimethyl-4-(2-(prop-2-yn-1-yloxy)ethoxy)aniline (3)

To the solution of compound **19** (9.16 g, 50.5 mmol, 1.0 eq.) in abs. THF (100 mL) at 0 °C, 60% NaH (3.03 g, 75.8 mmol, 1.5 eq.) was added in small portions over 30 min, then warmed until 25 °C. 80 wt% propargyl bromide in toluene (8.18 mL, ρ = 1.38 g/cm³,
75.9 mmol, 1.5 eq.) was added, and the reaction was left to stir for 16 h at 25 °C. The reaction mixture was quenched with water (50 mL) and extracted with DCM (2 × 100 mL); the organic phase was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and evaporated. Silica gel column chromatography (EtOH/Tol, gradient 0% → 20%) provided product **3** (yield: 8.73 g, 79%) as a brown amorphous solid. R_f = 0.67 (EtOH/Tol = 5:1). HPLC: t_R = 1.52 min, eluent E_1. IR (KBr) ν (cm⁻¹): 2923, 2852, 1513, 1455, 1352, 1242, 1104, 1035, 947, 817, 704. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 6.87 (d, 2H, ³J = 9.0 Hz, 2 × H-Ar), 6.73 (d, 2H, ³J = 9.0 Hz, 2 × H-Ar), 4.27 (s, 2H, (-CH₂-)), 4.10 (t, 2H, ³J = 4.4 Hz, (-CH₂-)), 3.87 (t, 2H, ³J = 4.4 Hz, (-CH₂-)), 2.87 (s, 6H, 2 × (-CH₃)), 2.45 (s, 1H, CH(alkynyl)). ¹³C NMR (126 MHz, CDCl₃) δ (ppm): 151.1, 146.2, 115.9, 114.8, 79.7, 74.8, 68.6, 68.1, 58.7, 41.8. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₁₃H₁₈NO₂ 220.1332; Found 220.1330 (0.91 ppm).

### 3.2.5. 6-Azido-9-(Tetrahydro-2H-pyran-2-yl)-9H-purine (11)

To a solution of 10 [69] (7.0 g, 29.33 mmol, 1.0 eq.) in DMF (240 mL) NaN₃ (3.81 g, 58.66 mmol, 2 eq.) was added, and the reaction mixture was stirred at 50 °C for 3 h. Then, it was evaporated and dried in a vacuum. The resulting solid was suspended in DCM (100 mL) and washed with 5% aqueous LiCl solution (2 × 100 mL), water (2 × 200 mL), and brine (100 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated, providing compound 11 (yield: 5.06 g, 70%) as a beige amorphous solid. HPLC: t_R = 3.00 min, eluent E₁. IR (KBr) ν (cm⁻¹): 2917, 2852, 2134, 1640, 1374, 1345, 1228, 1083, 1043, 967, 915. ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 10.12 (s, 1H, H-C(2)), 8.87 (s, 1H, H-C(8)), 5.90 (d, 1H, ³J = 11.2 Hz, Hₐ-C), 4.05 (d, 1H, ³J = 11.2 Hz, Hₑ-C), 3.77 (td, 1H, ²J = ³J = 11.2 Hz, ³J = 4.1 Hz, Hₑ-C), 2.42–2.35 (qd, 1H, ²J = ³J = 11.2 Hz, ³J = 4.1 Hz, Hₕ-C), 2.09–1.98 (m, 2H, Hₕ-C, Hₑ-C), 1.87–1.74 (m, 1H, Hₑ-C), 1.68–1.58 (m, 2H, (-CH₂-)). ¹³C-NMR (126 MHz, DMSO-d₆) δ (ppm): 145.4, 142.5, 141.5, 136.0, 119.9, 82.0, 67.8, 30.0, 24.4, 22.2. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₁₀H₁₂N₇O 246.1098; Found 246.1093 (2.03 ppm).

### 3.2.6. 2-({1-[9-(Tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl]-1H-1,2,3-triazol-4-yl}methoxy)ethan-1-ol (13)

**General method A for CuAAC reactions:** To a solution of **11** (1.0 g, 4.08 mmol, 1.0 eq.), CuI (0.14 g, 0.73 mmol, 0.18 eq.), AcOH (0.26 mL, ρ = 1.05 g/cm³, 4.49 mmol, 1.1 eq.) and Et₃N (0.63 mL, ρ = 0.73 g/cm³, 8.16 mmol, 2 eq.) in DCM (40 mL) 2-(prop-2-yn-1-yloxy)ethanol (0.82 g, 0.90 mmol, 1.5 eq.) (**12**) [70] was added and the reaction mixture was stirred isolated from the daylight for 1 h at 25 °C. Then, the reaction mixture was poured into water (50 mL) and extracted with DCM (3 × 50 mL). The combined organic phase was washed with aqueous NaHS (2 × 30 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and evaporated. Silica gel column chromatography (DCM/EtOH, gradient 0% → 15%) provided product **13** (yield: 881 mg, 63%) as a white amorphous solid. R_f = (0.48 DCM/EtOH = 10:1). HPLC: t_R = 2.16 min, eluent E₁. IR (KBr) ν (cm⁻¹): 3370, 3111, 2924, 2862, 1616, 1574, 1462, 1335, 1212, 1082, 1014, 908, 822. ¹H-NMR (500 MHz, CDCl₃) δ 9.07 (s, 1H, H-C(triazole)), 8.92 (s, 1H, H-C(2)), 8.42 (s, 1H, H-C(8)), 5.86 (dd, 1H, ²J = 10.5 Hz, ³J = 2.5 Hz, Hₐ-C), 4.84 (s, 2H, (-CH₂-)), 4.23–4.18 (m, 1H, Hₑ-C), 3.84–3.75 (m, 3H, Hₑ-C, (-CH₂-)), 3.74–3.70 (m, 2H, (-CH₂-)), 2.45 (s, 1H, (-OH)), 2.26–2.17 (m, 1H, Hₕ-C), 2.14–2.01 (m, 2H, Hₕ-C, Hₑ-C), 1.87–1.73 (m, 2H, Hₑ-C, H₉-C), 1.73–1.64 (m, 1H, H₉-C). ¹³C-NMR (126 MHz, CDCl₃) δ (ppm): 153.8, 152.3, 145.8, 144.9, 144.1, 123.2, 122.9, 82.6, 72.1, 69.1, 64.5, 62.0, 32.1, 24.9, 22.8. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₁₅H₂₀N₇O₃ 346.1622; Found 346.1613 (2.6 ppm).
### 3.2.7. N,N-Dimethyl-4-[2-[(1-[9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl]-1H-1,2,3-triazol-4-yl]methoxy)ethoxy]aniline (15)

Prepared according to general method A: Compound **11** (85 mg, 0.35 mmol, 1.0 eq.), CuI (12 mg, 0.06 mmol, 0.18 eq.), AcOH (23 µL, ρ = 1.05 g/cm³, 0.39 mmol, 1.1 eq.), Et₃N (54 µL, ρ = 0.73 g/cm³, 0.39 mmol, 1.1 eq.) and N,N-dimethyl-4-(2-(prop-2-yn-1-yloxy)ethoxy)aniline (115 mg, 0.52 mmol, 1.5 eq.), DCM (4 mL), 25 °C, 3 h. Silica gel column chromatography (Tol/EtOH, gradient 0% → 8%) provided product **15** (yield: 90 mg, 56%) as a gray amorphous solid. R_f = 0.49 (Tol/EtOH = 5:1). HPLC: t_R = 1.93 min, eluent E_1. IR (KBr) ν (cm⁻¹): 2939, 2869, 2801, 1614, 1523, 1456, 1231, 1209, 1083, 1032, 910, 803. ¹H-NMR (500 MHz, CDCl₃) δ 9.11 (s, 1H, H-C(triazole)), 8.92 (s, 1H, H-C(2)), 8.42 (s, 1H, H-C(8)), 6.85 (d, 2H, ³J = 6.5 Hz, 2 × H-C(Ar)), 6.68 (d, 2H, ³J = 6.5 Hz, 2 × H-C(Ar)), 5.85 (d, 1H, ³J = 10.5 Hz, H_a-C), 4.90 (s, 2H, (-CH₂-)), 4.20 (d, 1H, ³J = 10.5 Hz, H_e-C), 4.14–4.05 (m, 2H, (-CH₂-)), 3.95–3.88 (m, 2H, (-CH₂-)), 3.80 (t, 1H, ³J = 10.5 Hz, H_e-C), 2.83 (s, 6H, 2 × (-CH₃)), 2.23–2.16 (m, 1H, H_b-C), 2.13–2.01 (m, 2H, H_b-C, H_c-C), 1.87–1.72 (m, 2H, H_c-C, H_d-C), 1.71–1.64 (m, 1H, H_d-C). ¹³C-NMR (126 MHz, CDCl₃) δ (ppm): 153.8, 152.3, 151.0, 146.0, 145.9, 144.8, 144.0, 123.3, 122.8, 115.8, 114.7, 82.6, 69.4, 69.0, 68.2, 64.7, 41.8, 31.9, 24.9, 22.7. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₃H₂₉N₈O₃ 465.2357; Found 465.2355 (0.43 ppm).

### 3.2.8. 6-Chloro-9-[2-[(Tetrahydro-2H-pyran-2-yl)oxy]ethyl]-9H-purine (22)

To a suspension of 6-chloropurine (20) (4.8 g, 31.15 mmol, 1.1 eq.), PPh₃ (9.65 g, 36.82 mmol, 1.3 eq.) and 2-((tetrahydro-2H-pyran-2-yl)oxy)ethanol (21) [74] (4.14 g, 28.32 mmol, 1.0 eq.) in dry THF (200 mL) at 0 °C DIAD (6.12 mL, ρ = 1.03 g/cm³, 31.15 mmol, 1.1 eq.) was added slowly over 1 h. Then, the reaction mixture was left to stir for 16 h at 25 °C and then filtered. The filtrate was evaporated. Reverse phase silica gel column chromatography (MeOH/H₂O, gradient 0% → 70%) provided product 22 (yield: 4.82 g, 55%) as a pale yellow oil. R_f = 0.84 (DCM/EtOH = 10:1). HPLC: t_R = 2.15 min, eluent E_1. IR (KBr) ν (cm⁻¹): 2941, 2867, 1593, 1560, 1334, 1197, 1123, 1034, 933, 856. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 8.73 (s, 1H, H-C(2)), 8.28 (s, 1H, H-C(8)), 4.56–4.45 (m, 3H, H_a-C, (-CH₂-)), 4.11–4.05 (m, 1H, H_f-C), 3.77–3.71 (m, 1H, H_f-C), 3.61–3.54 (m, 1H, H_e-C), 3.44–3.38 (m, 1H, H_e-C), 1.77–1.62 (m, 2H, H_b-C, H_c-C), 1.57–1.45 (m, 4H, H_b-C, H_c-C, (-CH₂-)). ¹³C-NMR (126 MHz, CDCl₃) δ (ppm): 152.0, 151.9, 151.0, 146.5, 131.6, 99.3, 65.2, 62.6, 44.4, 30.5, 25.3, 19.5. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₁₂H₁₆ClN₄O₂ 283.0956; Found 283.0950 (2.12 ppm).

### 3.2.9. 6-Azido-9-[2-[(Tetrahydro-2H-pyran-2-yl)oxy]ethyl]-9H-purine (23)

To a solution of **22** (0.72 g, 2.54 mmol, 1.0 eq.) in DMF (14 mL) NaN₃ (0.33 g, 5.08 mmol, 2 eq.) was added and the reaction mixture was stirred at 50 °C for 16 h. Then, it was evaporated and dried in a vacuum. The resulting solid was suspended in DCM (20 mL) and washed with 5% aqueous LiCl solution (2 × 20 mL), water (2 × 20 mL), and brine (20 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated, providing compound **23** (yield: 0.73 g, 99%) as a white amorphous solid. HPLC: t_R = 2.94 min, eluent E_1. IR (KBr) ν (cm⁻¹): 2985, 2938, 2185, 1636, 1376, 1345, 1256, 1125, 1071, 981, 872. ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 10.11 (s, 1H, H-C(2)), 8.63 (s, 1H, H-C(8)), 4.68–4.55 (m, 3H, H_a-C, (-CH₂-)), 4.02 (ddd, 1H, ²J = 10.9 Hz, ³J = 6.5, 4.1 Hz, H_f-C), 3.84 (ddd, 1H, ²J = 10.9 Hz, ³J = 6.5, 4.1 Hz, H_f-C), 3.44 (ddd, 1H, ²J = 11.2 Hz, ³J = 8.4, 3.0 Hz, H_e-C), 3.32–3.29 (m, 1H, H_e-C), 1.64–1.48 (m, 2H, H_b-C, H_c-C), 1.45–1.31 (m, 4H, H_b-C, H_c-C, (-CH₂-)). ¹³C NMR (126 MHz, DMSO-d₆) δ (ppm): 145.4, 144.7, 142.3, 135.7, 119.6, 97.6, 64.6, 61.1, 44.3, 29.9, 24.8, 18.8. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₁₂H₁₆N₇O₂ 290.1360; Found 290.1350 (3.45 ppm).
3.2.10. *N*,*N*-Dimethyl-4-(2-{[1-(9-{2-[(Tetrahydro-2*H*-pyran-2-yl)oxy]ethyl}-9*H*-purin-6-yl)-1*H*-1,2,3-triazol-4-yl]methoxy}ethoxy)aniline (24)

Prepared according to general method A: Compound **23** (100 mg, 0.35 mmol, 1.0 eq.), Cul (12 mg, 0.06 mmol, 0.16 eq.), AcOH (21 µL, ρ = 1.05 g/cm³, 0.38 mmol, 1.1 eq.), Et₃N (53 µL, ρ = 0.73 g/cm³, 0.38 mmol, 1.1 eq.) and *N*,*N*-dimethyl-4-(2-(prop-2-yn-1-yloxy)ethoxy)aniline (151 mg, 0.69 mmol, 2.0 eq.), DCM (3 mL), 25 °C, 1 h. Silica gel column chromatography (DCM/EtOH, gradient 0% → 5%) provided product **24** (yield: 81 mg, 46%) as a pale brown amorphous solid. R_f = 0.53 (DCM/EtOH = 20:1). HPLC: t_R = 5.03 min, eluent E_2. IR (KBr) ν (cm⁻¹): 2919, 2868, 1605, 1513, 1331, 1234, 1111, 1032, 845, 823. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 9.11 (s, 1H, H-C(triazole)), 8.91 (s, 1H, H-C(2)), 8.39 (s, 1H, H-C(8)), 6.86 (d, 2H, ³J = 9.2 Hz, 2 × H-C(Ar)), 6.70 (d, 2H, ³J = 9.2 Hz, 2 × H-C(Ar)), 4.90 (s, 2H, (-CH₂-)), 4.64–4.51 (m, 3H, Hₐ-C, (-CH₂-)), 4.17–4.12 (m, 1H, Hf-C), 4.11 (dd, 2H, ³J = 6.0, 4.0 Hz, (-CH₂-)), 3.92 (dd, 2H, ³J = 6.0, 4.0 Hz, (-CH₂-)), 3.78 (ddd, 1H, ²J = 10.7 Hz, ³J = 7.1, 3.4 Hz, Hf-C), 3.62–3.56 (m, 1H, Hₑ-C), 3.46–3.39 (m, 1H, Hₑ-C), 2.83 (s, 6H, 2 × (-CH₃)), 1.80–1.64 (m, 2H, Hb-C, Hc-C), 1.59–1.45 (m, 4H, Hb-C, Hc-C, (-CH₂-)). ¹³C-NMR (126 MHz, CDCl₃) δ (ppm): 154.6, 152.1, 151.1, 147.3, 146.0, 145.9, 144.7, 123.3, 122.6, 115.8, 114.8, 99.3, 69.4, 68.2, 65.2, 64.8, 62.6, 44.4, 41.8, 30.5, 25.2, 19.4. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₅H₃₃N₈O₄ 509.2619; Found 509.2624 (0.98 ppm).

3.2.11. 2-Bromo-*N*,*N*-Dimethyl-4-{2-[(1-(9-{2-[(Tetrahydro-2*H*-pyran-2-yl)oxy]ethyl}-9*H*-purin-6-yl)-1*H*-1,2,3-triazol-4-yl)methoxy}ethoxy}aniline (25)

To a solution of **24** (100 mg, 0.2 mmol, 1.0 eq.) in CHCl₃ (3 mL) at 0 °C NBS (37 mg, 0.21 mmol, 1.05 eq.) was slowly added. The reaction mixture was left to stir for 1 h at 0 °C, then diluted with CHCl₃ to 20 mL in total, washed with water (3 × 50 mL) and brine (20 mL), then evaporated and dried in a vacuum. Silica gel column chromatography (DCM/EtOH, gradient 0% → 10%) provided product **25** (yield: 68 mg, 59%) as a brown oil. R_f = 0.85 (DCM/EtOH = 10:1). HPLC: t_R = 5.37 min, eluent E_2. IR (KBr) ν (cm⁻¹): 2940, 2867, 1604, 1575, 1331, 1223, 1122, 1031, 991, 850. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 9.14 (s, 1H, H-C(triazole)), 8.94 (s, 1H, H-C(2)), 8.42 (s, 1H, H-C(8)), 7.20 (d, 1H, ⁴J = 2.8 Hz, H-C(Ar)), 7.02 (d, 1H, ³J = 8.9 Hz, H-C(Ar)), 6.85 (dd, 1H, ³J = 8.9 Hz, ⁴J = 2.8 Hz, H-C(Ar)), 4.91 (s, 2H, (-CH₂-)), 4.66–4.51 (m, 3H, Hₐ-C, (-CH₂-)), 4.17–4.13 (m, 1H, Hf-C), 4.12 (dd, 2H, ³J = 5.7, 3.6 Hz, (-CH₂-)), 3.94 (dd, 2H, ³J = 5.7, 3.6 Hz, (-CH₂-)), 3.79 (ddd, 1H, ²J = 10.7 Hz, ³J = 7.1, 3.3 Hz, Hf-C), 3.65–3.58 (m, 1H, Hₑ-C), 3.47–3.40 (m, 1H, Hₑ-C), 2.71 (s, 6H, 2 × (-CH₃)), 1.81–1.69 (m, 2H, Hb-C, Hc-C), 1.59–1.44 (m, 4H, Hb-C, Hc-C, (-CH₂-)). ¹³C-NMR (126 MHz, CDCl₃) δ (ppm): 155.1, 154.6, 152.2, 147.4, 145.9, 145.7, 144.8, 123.3, 122.6, 121.1, 120.2, 115.9, 114.3, 99.4, 69.1, 68.1, 65.3, 64.8, 62.7, 44.9, 44.4, 30.5, 25.3, 19.5. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₅H₃₂BrN₈O₄ 587.1724; Found 587.1707 (2.90 ppm).

3.2.12. 6-Chloro-8-iodo-9-{2-[(Tetrahydro-2*H*-pyran-2-yl)oxy]ethyl}-9*H*-purine (26)

To dry, degassed THF (96 mL) at -78 °C DIPEA (3.71 mL, ρ = 0.72 g/cm³, 26.31 mmol, 1.55 eq.) and *n*-BuLi (10.38 mL, 2.29 M, 23.77 mmol, 1.4 eq.) were added and left to stir for 30 min at -78 °C. Compound **22** (4.8 g, 16.98 mmol, 1.0 eq.) was dissolved in dry, degassed THF (48 mL), slowly added to the solution of LDA at -78 °C, and left to stir for 1 h at that temperature. I₂ (21.5 g, 84.89 mmol, 5.0 eq.) was dissolved in dry, degassed THF (20 mL) and slowly added to the reaction mixture until it became solid. Then, the reaction was warmed up to room temperature, and saturated aqueous Na₂S₂O₃·5H₂O solution was added until the aqueous phase became colorless. The reaction mixture was washed with EtOAc (3 × 150 mL), and the combined organic phase was washed with brine (100 mL) and dried over anhydrous Na₂SO₄, filtered, and evaporated. Silica gel column chromatography (DCM/EtOH, gradient 0% → 5%) provided product **26** (yield: 6.34 g, 91%) as a pale brown amorphous solid. R_f = 0.65 (DCM/EtOH = 20:1). HPLC: t_R = 4.66 min, eluent E_1. IR (KBr)
ν (cm⁻¹): 2940, 2865, 1587, 1558, 1454, 1321, 1150, 1123, 1068, 1037, 948, 866. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 8.65 (s, 1H, H-C(2)), 4.58–4.41 (m, 3H, Hₐ-C, (-CH₂-)), 4.10 (ddd, 1H, ²J = 11.1 Hz, ³J = 6.8, 4.5 Hz, Hf-C), 3.81 (ddd, 1H, ²J = 11.1 Hz, ³J = 6.8, 4.5 Hz, Hf-C), 3.48 (td, 1H, ²J = 11.4 Hz, ³J = 3.3 Hz, Hₑ-C), 3.41–3.34 (m, 1H, Hₑ-C), 1.73–1.57 (m, 2H, Hb-C, Hc-C), 1.54–1.40 (m, 4H, Hb-C, Hc-C, (-CH₂-)). ¹³C-NMR (126 MHz, CDCl₃) δ (ppm): 153.1, 151.9, 149.3, 134.0, 109.1, 98.5, 64.3, 62.0, 46.6, 30.2, 25.3, 19.0. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₁₂H₁₅ClN₄O₂ 408.9923; Found 408.9913 (2.45 ppm).

### 3.2.13. 4-(6-Chloro-9-{2-[(Tetrahydro-2H-pyran-2-yl)oxy]ethyl}-9H-purin-8-yl)-N,N-Dimethylaniline (27)

In the pressure flask a solution of compound 26 (825 mg, 2.02 mmol, 1.0 eq.), N,N-dimethyl-4-(tributylstannyl)aniline [68] (911 mg, 2.22 mmol, 1.1 eq.) and Pd(PPh₃)₄ (116 mg, 0.1 mmol, 0.05 eq.) in dry toluene (25 mL) was stirred at 110 °C for 16 h. Then, it was evaporated and dried in a vacuum. Silica gel column chromatography (DCM/EtOH, gradient 0% → 25%) provided product 27 (yield: 420 mg, 52%) as a pale orange amorphous solid. R<sub>f</sub> = 0.60 (DCM/EtOH = 20:1). HPLC: t<sub>R</sub> = 5.89 min, eluent E<sub>1</sub>. IR (KBr) ν (cm⁻¹): 2930, 2863, 1609, 1479, 1365, 1343, 1125, 1037, 978, 948, 819. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 8.67 (s, 1H, H-C(2)), 7.91 (d, 2H, ³J = 8.6 Hz, 2 × H-C(Ar)), 6.78 (d, 2H, ³J = 8.6 Hz, 2 × H-C(Ar)), 4.65–4.55 (m, 2H, (-CH₂-)), 4.53–4.48 (m, 1H, Hₐ-C), 4.26–4.16 (m, 1H, Hf-C), 4.00–3.90 (m, 1H, Hf-C), 3.56–3.47 (m, 1H, Hₑ-C), 3.43–3.35 (m, 1H, Hₑ-C), 3.07 (s, 6H, 2 × (-CH₃)), 1.75–1.59 (m, 2H, Hb-C, Hc-C), 1.55–1.40 (m, 4H, Hb-C, Hc-C, (-CH₂-)). ¹³C-NMR (126 MHz, CDCl₃) δ (ppm): 157.8, 154.3, 152.0, 150.8, 148.7, 131.8, 131.2, 115.6, 111.8, 98.8, 64.7, 62.0, 44.7, 40.3, 30.3, 25.3, 19.2. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₀H₂₅ClN₅O₂ 402.1691; Found 402.1685 (1.49 ppm).

### 3.2.14. 4-(6-Azido-9-{2-[(Tetrahydro-2H-pyran-2-yl)oxy]ethyl}-9H-purin-8-yl)-N,N-Dimethylaniline (28)

To a solution of 27 (2.84 g, 7.07 mmol, 1.0 eq.) in DMF (140 mL) NaN₃ (1.40 g, 21.22 mmol, 3.0 eq.) was added and the reaction mixture was stirred at 60 °C for 16 h. Then, the reaction mixture was poured into cold water (1 L), and the precipitate was filtered and washed with water (0.5 L), providing compound 28 (yield: 2.69 g, 93%) as a pale pink amorphous solid. HPLC: t<sub>R</sub> = 4.66 min, eluent E<sub>1</sub>. IR (KBr) ν (cm⁻¹): 2939, 2886, 2025, 1608, 1478, 1344, 1202, 1126, 1073, 977, 874, 821. ¹H-NMR (500 MHz, DMSO-d₆) δ (ppm): 10.08 (s, 1H, H-C(2)), 7.86 (d, 2H, ³J = 8.7 Hz, 2 × H-C(Ar)), 6.86 (d, 2H, ³J = 8.7 Hz, 2 × H-C(Ar)), 4.48–4.45 (m, 2H, (-CH₂-)), 4.48–4.43 (m, 1H, Hₐ-C), 4.06 (ddd, 1H, ²J = 11.2 Hz, ³J = 6.7, 4.7 Hz, Hf-C), 3.86 (ddd, 1H, ²J = 11.2 Hz, ³J = 6.7, 4.7 Hz, Hf-C), 3.35–3.30 (m, 1H, Hₑ-C), 3.26–3.22 (m, 1H, Hₑ-C), 3.02 (s, 6H, 2 × (-CH₃)), 1.47–1.40 (m, 2H, Hb-C, Hc-C), 1.37–1.24 (m, 4H, Hb-C, Hc-C, (-CH₂-)). ¹³C-NMR (126 MHz, DMSO-d₆) δ (ppm): 154.6, 151.4, 144.9, 144.0, 134.4, 130.3, 119.6, 115.6, 111.6, 97.5, 64.2, 60.8, 44.7, 39.72, 29.7, 24.7, 18.6. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₀H₂₅N₈O₂ 409.2095; Found 409.2097 (0.49 ppm).

### 3.2.15. 4-[6-(4-({2-[4-(Dimethylamino)phenoxy]ethoxy)methyl}-1H-1,2,3-triazol-1-yl)-9-[2-[(Tetrahydro-2H-pyran-2-yl)oxy]ethyl]-9H-purin-8-yl]-N,N-Dimethylaniline (29)

Prepared according to general method A: Compound 28 (500 mg, 1.22 mmol, 1.0 eq.), Cul (40 mg, 0.20 mmol, 0.16 eq.), AcOH (77 µL, ρ = 1.05 g/cm³, 1.35 mmol, 1.1 eq.), Et₃N (187 µL, ρ = 0.73 g/cm³, 1.35 mmol, 1.1 eq.) and N,N-dimethyl-4-(2-(prop-2-yn-1-yloxy)ethoxy)aniline (540 mg, 2.45 mmol, 2.0 eq.), DCM (20 mL), 25 °C, 16 h. Silica gel column chromatography (DCM/EtOH, gradient 0% → 3%) provided product 29 (yield: 420 mg, 55%) as a brown amorphous solid. R<sub>f</sub> = 0.43 (DCM/EtOH = 20:1). HPLC: t<sub>R</sub> = 4.15 min, eluent E<sub>1</sub>. IR (KBr) ν (cm⁻¹): 2923, 2855, 1606, 1512, 1457, 1338, 1243, 1118, 1032, 816, 797. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 9.40 (s, 1H, H-C(triazole)), 8.88 (s,
1H, H-C(2)), 7.96 (d, 2H, $^3J$ = 8.6 Hz, 2 × H-C(Ar)), 6.85 (d, 2H, $^3J$ = 8.6 Hz, 2 × H-C(Ar)), 6.78 (d, 2H, $^3J$ = 8.6 Hz, 2 × H-C(Ar)), 6.67 (d, 2H, $^3J$ = 8.6 Hz, 2 × H-C(Ar)), 4.91 (s, 2H, (-CH₂-)), 4.72–4.62 (m, 2H, (-CH₂-)), 4.54–4.49 (m, 1H, Hₐ-C), 4.25 (ddd, 1H, $^2J$ = 11.0 Hz, $^3J$ = 5.6, 5.2 Hz, Hf-C), 4.10 (t, 2H, $^3J$ = 4.7 Hz, (-CH₂-)), 3.98 (ddd, 1H, $^2J$ = 11.0 Hz, $^3J$ = 5.6, 5.2 Hz, Hf-C), 3.92(t, 2H, $^3J$ = 4.7 Hz, (-CH₂-)), 3.55–3.48 (m, 1H, He-C), 3.40–3.34 (m, 1H, He-C), 3.07 (s, 6H, 2 × (-CH₃)), 2.82 (s, 6H, 2 × (-CH₃)), 1.64–1.54 (m, 2H, Hb-C, Hc-C), 1.51–1.36 (m, 4H, Hb-C, Hc-C, (-CH₂-)). $^{13}$C NMR (126 MHz, CDCl₃) δ 158.4, 157.0, 152.1, 151.1, 151.0, 146.0, 145.8, 142.9, 131.2, 124.5, 122.8, 115.8, 115.5, 114.8, 111.7, 98.8, 69.1, 68.2, 64.68, 64.67, 62.0, 44.7, 41.8, 40.2, 30.3, 25.3, 19.1. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₃₃H₄₂N₉O₄ 628.3354; Found 628.3383 (4.62 ppm).

3.2.16. 2-{6-[4-({2-[4-(Dimethylamino)phenoxy]ethoxy)methyl]-1H-1,2,3-triazol-1-yl]-8-[4-(Dimethylamino)phenyl]-9H-purin-9-yl]ethan-1-ol (30)

To the mixture of compound 29 (815 mg, 1.30 mmol, 1.0 eq.) in 52 mL of MeOH/H₂O/DCM mixture (10:2:1) TFA (0.99 mL, ρ = 1.49 g/cm³, 13.0 mmol, 10.0 eq.) was added at 25 °C. Then, the reaction was left stirring for 2 h, evaporated, dissolved in DCM (10 mL), and washed with aqueous NaHCO₃ solution (10 mL) and brine (10 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated, providing product 30 (yield: 689 mg, 98%) as a dark yellow amorphous solid. Rf = 0.68 (DCM/EtOH = 10:1). HPLC: tR = 6.32 min, eluent E₂. IR (KBr) ν (cm⁻¹): 3339, 2873, 1606, 1513, 1483, 1338, 1229, 1200, 1033, 950, 819. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 9.28 (s, 1H, H-C(triazole)), 8.78 (s, 1H, H-C(2)), 7.81 (d, 2H, $^3J$ = 8.8 Hz, 2 × H-C(Ar)), 6.85 (d, 2H, $^3J$ = 8.6 Hz, 2 × H-C(Ar)), 6.75 (d, 2H, $^3J$ = 8.8 Hz, 2 × H-C(Ar)), 6.68 (d, 2H, $^3J$ = 8.6 Hz, 2 × H-C(Ar)), 4.89 (s, 2H, (-CH₂-)), 4.55 (t, 2H, $^3J$ = 5.0 Hz, (-CH₂-)), 4.22 (t, 2H, $^3J$ = 5.0 Hz, (-CH₂-)), 4.10 (t, 2H, $^3J$ = 4.7 Hz, (-CH₂-)), 3.92 (t, 2H, $^3J$ = 4.7 Hz, (-CH₂-)), 3.06 (s, 6H, 2 × (-CH₃)), 2.82 (s, 6H, 2 × (-CH₃)). $^{13}$C-NMR (126 MHz, CDCl₃) δ (ppm): 158.6, 156.8, 152.1, 151.3, 150.6, 146.0, 145.9, 142.7, 131.4, 124.2, 122.7, 115.8, 115.0, 114.9, 111.8, 69.3, 68.2, 64.7, 61.2, 48.2, 42.0, 40.2. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₈H₃₄N₉O₃ 544.2779; Found 544.2805 (4.78 ppm).

3.2.17. 2-{6-[4-({2-[4-(Dimethylamino)phenoxy]ethoxy)methyl]-1H-1,2,3-triazol-1-yl]-8-[4-(Dimethylamino)phenyl]-9H-purin-9-yl]ethyl Methanesulfonate (31)

To a solution of compound 30 (689 mg, 1.27 mmol, 1.0 eq.) in DCM (5 mL), Et₃N (176 µL, ρ = 0.73 g/cm³, 1.27 mmol, 1.0 eq.) was added. The reaction mixture was cooled to 0 °C. MsCl (0.11 mL, ρ = 1.48 g/cm³, 1.46 mmol, 1.15 eq.) was slowly added dropwise to the reaction mixture, and it was left to stir for 1 h at 25 °C. Then, the reaction mixture was washed with H₂O (2 × 10 mL) and brine (10 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and poured in cold hexane (200 mL). The resulting precipitate was filtered, providing product 31 (yield: 772 mg, 98%) as a dark orange amorphous solid. HPLC: tR = 5.34 min, eluent E₂. IR (KBr) ν (cm⁻¹): 2929, 2868, 1608, 1514, 1477, 1339, 1221, 1170, 1038, 898, 810. ¹H-NMR (500 MHz, CDCl₃) δ (ppm): 9.34 (s, 1H, H-C(triazole)), 8.86 (s, 1H, H-C(2)), 7.76 (d, 2H, $^3J$ = 8.4 Hz, 2 × H-C(Ar)), 6.86 (d, 2H, $^3J$ = 8.8 Hz, 2 × H-C(Ar)), 6.82 (d, 2H, $^3J$ = 8.8 Hz, 2 × H-C(Ar)), 6.77 (d, 2H, $^3J$ = 8.4 Hz, 2 × H-C(Ar)), 4.89 (s, 2H, (-CH₂-)), 4.84–4.77 (m, 2H, (-CH₂-)), 4.74–4.68 (m, 2H, (-CH₂-)), 4.15–4.07 (m, 2H, (-CH₂-)), 3.95–4.89 (m, 2H, (-CH₂-)), 3.06 (s, 6H, 2 × (-CH₃)), 2.87 (s, 6H, 2 × (-CH₃)), 2.84 (s, 3H, (-CH₃)). $^{13}$C NMR (126 MHz, CDCl₃) δ (ppm): 157.9, 156.8, 152.7, 152.2, 151.2, 145.8, 144.1, 143.1, 130.8, 124.4, 122.8, 116.1, 115.9, 114.6, 111.9, 69.1, 68.1, 65.6, 64.6, 43.8, 42.8, 40.2, 37.6. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₉H₃₆N₉O₅S 622.2555; Found 625.2549 (0.94 ppm).
3.2.18. 4-((6-((2-((4-(Dimethylamino)phenoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)-9-(2-(4,7,10-trimethyl-1,4,7,10-tetraazacyclododecan-1-yl)ethyl)-9H-purin-8-yl)-N,N-Dimethylaniline (1)

A suspension of compound **31** (770 mg, 1.24 mmol, 1.0 eq.) and LiBr (215 mg, 2.48 mmol, 2.0 eq.) in THF (16 mL) was stirred in a pressure flask at 70 °C for 3 h. Then, the reaction mixture was evaporated, suspended in DCM (10 mL), and washed with water (2 × 10 mL) and brine (10 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered, and evaporated. 1,4,7-Trimethyl-1,4,7,10-tetraazacyclododecane [75] (2.66 g, 12.4 mmol, 10 eq.) was added to the precipitate, and this mixture was dissolved in abs. MeCN (60 mL) and left to stir for 72 h at 25 °C. Silica gel column chromatography (DCM/EtOH, gradient 0% → 5%) provided by-product **32** (yield: 370 mg, 57%) as a yellow amorphous solid. Reverse phase silica gel column chromatography (MeOH/H₂O, gradient 0% → 70%) with the following preparative HPLC column chromatography (that used TFA as an additive) was used to separate impurities from the product. Then, it was dissolved in DCM (10 mL), washed with sat. aqueous NaHCO₃ solution (10 mL) and brine (10 mL), and evaporated. Next, it was dissolved in water (10 mL), filtered, and lyophilized, providing product **1** (yield: 56 mg, 6%) as a yellow amorphous solid. R_f = 0.1 (DCM/EtOH = 20:1). HPLC: t_R = 4.38 min, eluent E₂. IR (KBr) ν(cm⁻¹): 2924, 2852, 1667, 1607, 1585, 1464, 1338, 1259, 1066, 1033, 796. ¹H-NMR (500 MHz, CDCl₃) δ 9.41 (ppm) (s, 1H, H-C(triazole)), 8.89 (s, 1H, H-C(2)), 7.83 (d, 2H, ³J = 8.8 Hz, 2 × H-C(Ar)), 6.86 (d, 2H, ³J = 9.0 Hz, 2 × H-C(Ar)), 6.80 (d, 2H, ³J = 8.8 Hz, 2 × H-C(Ar)), 6.67 (d, 2H, ³J = 9.0 Hz, 2 × H-C(Ar)), 4.92 (s, 2H, (-CH₂-)), 4.59 (t, 2H, ³J = 6.8 Hz, (-CH₂-)), 4.11 (t, 2H, ³J = 4.8 Hz, (-CH₂-)), 3.92 (t, 2H, ³J = 4.8 Hz, (-CH₂-)), 3.07 (s, 6H, 2 × (CH₃)), 2.82 (s, 6H, 2 × (CH₃)), 2.77 (t, 2H, ³J = 6.8 Hz, (-CH₂-)), 2.65-2.61 (m, 4H, 2 × (-CH₂-)), 2.32-2.26 (m, 12H, 6 × (-CH₂-)), 2.16 (s, 3H, (-CH₃)), 2.11 (s, 6H, 2 × (-CH₃)). ¹H-NMR (500 MHz, MeCN-d₃) δ 9.27 (ppm) (s, 1H, H(1)), 8.84 (s, 1H, H(2)), 7.85 (d, 2H, ³J = 8.6 Hz, 2 × H(3)), 6.88 (d, 2H, ³J = 8.6 Hz, 2 × H(4)), 6.81 (d, 2H, ³J = 9.1 Hz, 2 × H(5)), 6.66 (d, 2H, ³J = 9.1 Hz, 2 × H(6)), 4.81 (s, 2H, 2 × H(7)), 4.61 (t, 2H, ³J = 6.6 Hz, 2 × H(8)), 4.07 (t, 2H, ³J = 4.6 Hz, 2 × H(9)), 3.86 (t, 2H, ³J = 4.6 Hz, 2 × H(10)), 3.05 (s, 6H, 6 × H(11)), 2.86-2.74 (m, 8H, 6 × H(12), 2 × H(13)), 2.58-2.51 (m, 4H, 4 × H(14)), 2.46-2.17 (m, 21H, 12 × H(15), 9 × H(16)). ¹³C NMR (126 MHz, CDCl₃) δ (ppm): 157.8, 157.2, 152.1, 151.13, 151.03, 146.0, 145.8, 142.9, 130.7, 124.6, 122.7, 115.9, 115.8, 114.8, 111.9, 69.1, 68.2, 64.7, 56.4, 55.79, 55.75, 54.6, 53.4, 45.0, 44.4, 42.9, 41.8, 40.2. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₃₉H₅₈N₁₃O₂ 740.4831; Found 740.4846 (2.03 ppm).

3.2.19. 4-((6-((2-((4-(Dimethylamino)phenoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)-9-vinyl-9H-purin-8-yl)-N,N-Dimethylaniline (32)

R_f = 0.61 (DCM/EtOH = 20:1). HPLC: t_R = 6.21 min, eluent E₂. IR (KBr) ν (cm⁻¹): 2925, 2865, 1606, 1480, 1342, 1199, 1124, 1036, 1023, 946, 819. ¹H NMR (500 MHz, CDCl₃) δ 9.39 (s, 1H, H-C(triazole)), 8.95 (s, 1H, H-C(2)), 7.84 (d, 2H, ³J = 8.6 Hz, 2 × H-C(Ar)), 7.07 (dd, 1H, ³J = 15.8, 8.9 Hz, (-CHₐ)), 6.86 (d, 2H, ³J = 8.6 Hz, 2 × H-C(Ar)), 6.81 (d, 2H, ³J = 8.6 Hz, 2 × H-C(Ar)), 6.68 (d, 2H, ³J = 8.6 Hz, 2 × H-C(Ar)), 6.43 (d, 1H, ²J = 15.8 Hz, (-CHb)), 5.51 (d, 1H, ³J = 8.9 Hz, (-CHc)), 4.93 (s, 2H, (-CH₂-)), 4.12 (t, 2H, ³J = 4.8 Hz, (-CH₂-)), 3.94 (t, 2H, ³J = 4.8 Hz, (-CH₂-)), 3.09 (s, 6H, 2 × (-CH₃)), 2.83 (s, 6H, 2 × (-CH₃)). ¹³C NMR (126 MHz, CDCl₃) δ (ppm): 156.8, 156.2, 152.3, 151.5, 151.1, 146.0, 145.9, 143.2, 131.6, 128.4, 124.5, 123.4, 115.9, 114.8, 114.7, 111.7, 110.9, 69.2, 68.3, 64.7, 41.8, 40.2. HRMS (ESI) m/z: [M + H]⁺ Calculated for C₂₈H₃₂N₉O₂ 526.2673; Found 526.2688 (2.85 ppm).

4. Conclusions

We have developed a new synthetic approach toward the proposed purine-cyclen conjugate using the sequence of modifications, which includes Mitsunobu, iodination, Stille, S_NAr, CuAAC, and alkylation reactions as main transformations. The optimal sequence
of derivatization (positions: N9 → C8 → C6 → N9) was found as the result of several less successful attempts toward the target compound. Purine-cyclen conjugate was obtained in nine steps, starting from commercially available 6-chloropurine. As the main by-product, the N9-vinyl group containing purine-triazole conjugate was obtained, which was formed via the E2 type reaction mechanism between purine alkyl bromide derivative and modified cyclen moiety. Preliminary NMR and UV titration experiments revealed that target purine-cyclen conjugate easily complexes copper(II) ions in the cyclen ring and between triazole N2 and purine N7 positions. Photophysical and photocatalytic properties of the developed purine-cyclen derivatives will be studied in the future and will be reported elsewhere.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules30071612/s1, ¹H- and ¹³C-NMR spectra of compounds 1, 3, 11, 13, 15, 22–32; NMR titration procedure and stacked spectra for the titration experiments of compound 1.

**Author Contributions:** Synthetic experiments, investigation, methodology, and manuscript draft, A.B.; conceptualization, the idea of the purine-cyclen conjugate, spectrophotometric analysis, and manuscript review, G.J.; conceptualization, supervision, and manuscript review, I.N. and M.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** The authors acknowledge the financial support provided by the Latvia-Lithuania-Taiwan joint grant #LV-LT-TW/2022/9 "Molecular Electronics in Functionalized Purines: Fundamental Study and Applications (MEPS)" from the Latvian Council of Science. I.N. and G.J. acknowledge the PHC Osmosis program project (#50602NB for France, #LV-FR/2024/5 for Latvia) "Purine-based carbenes: synthesis, photophysical and optical studies (PBC)" for financial support of scientific exchanges.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding authors.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Müller, C.E.; Thorand, M.; Qurishi, R.; Diekmann, M.; Jacobson, K.A.; Padgett, W.L.; Daly, J.W. Imidazo[2,1-i]Purin-5-Ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A<sub>2A</sub>- and A<sub>3</sub>-Adenosine Receptor Antagonist. *J. Med. Chem.* **2002**, *45*, 3440–3450. [CrossRef] [PubMed]

2. Al Jaroudi, W.; Iskandrian, A.E. Regadenoson: A New Myocardial Stress Agent. *J. Am. Coll. Cardiol.* **2009**, *54*, 1123–1130. [CrossRef] [PubMed]

3. Shelton, J.; Lu, X.; Hollenbaugh, J.A.; Cho, J.H.; Amblard, F.; Schinazi, R.F. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. *Chem. Rev.* **2016**, *116*, 14379–14455. [CrossRef] [PubMed]

4. Parker, W.B. Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. *Chem. Rev.* **2009**, *109*, 2880–2893. [CrossRef]

5. Xu, W.; Chan, K.M.; Kool, E.T. Fluorescent Nucleobases as Tools for Studying DNA and RNA. *Nat. Chem.* **2017**, *9*, 1043–1055. [CrossRef]

6. Sinkeldam, R.W.; Greco, N.J.; Tor, Y. Fluorescent Analogs of Biomolecular Building Blocks: Design, Properties, and Applications. *Chem. Rev.* **2010**, *110*, 2579–2619. [CrossRef]

7. Dumas, A.; Luedtke, N.W. Site-Specific Control of N7-Metal Coordination in DNA by a Fluorescent Purine Derivative. *Chem.-A Eur. J.* **2012**, *18*, 245–254. [CrossRef]

8. Omumi, A.; McLaughlin, C.K.; Ben-Israel, D.; Manderville, R.A. Application of a Fluorescent C-Linked Phenolic Purine Adduct for Selective N7-Metalation of DNA. *J. Phys. Chem. B* **2012**, *116*, 6158–6165. [CrossRef]

9. Sun, K.M.; McLaughlin, C.K.; Lantero, D.R.; Manderville, R.A. Biomarkers for Phenol Carcinogen Exposure Act as pH-Sensing Fluorescent Probes. *J. Am. Chem. Soc.* **2007**, *129*, 1894–1895. [CrossRef]

10. Venkatesh, V.; Shukla, A.; Sivakumar, S.; Verma, S. Purine-Stabilized Green Fluorescent Gold Nanoclusters for Cell Nuclei Imaging Applications. *ACS Appl. Mater. Interfaces* **2014**, *6*, 2185–2191. [CrossRef]
11. Li, J.; Zhang, Y.; Zhang, H.; Xuan, X.; Xie, M.; Xia, S.; Qu, G.; Guo, H. Nucleoside-Based Ultrasensitive Fluorescent Probe for the Dual-Mode Imaging of Microviscosity in Living Cells. *Anal. Chem.* **2016**, *88*, 5554–5560. [CrossRef] [PubMed]

12. Wang, Z.; Yao, J.; Zhan, L.; Gong, S.; Ma, D.; Yang, C. Purine-Based Thermally Activated Delayed Fluorescence Emitters for Efficient Organic Light-Emitting Diodes. *Dye. Pigment.* **2020**, *180*, 108437. [CrossRef]

13. Kong, B.; Joshi, T.; Belousoff, M.J.; Tor, Y.; Graham, B.; Spiccia, L. Neomycin B-Cyclen Conjugates and Their Zn(II) Complexes as RNA-Binding Agents. *J. Inorg. Biochem.* **2016**, *162*, 334–342. [CrossRef]

14. Abdollahi, M.; Hosseini, A. Hydrogen Sulfide. In *Encyclopedia of Toxicology*, 3rd ed.; Wexler, P., Ed.; Elsevier: Amsterdam, The Netherlands, 2014; pp. 971–974, ISBN 9780123864550.

15. Lima, L.M.P.; Esteban-Gómez, D.; Delgado, R.; Platas-Iglesias, C.; Tripier, R. Monopicolinate Cyclen and Cyclam Derivatives for Stable Copper(II) Complexation. *Inorg. Chem.* **2012**, *51*, 6916–6927. [CrossRef]

16. Delgado, R.; Félix, V.; Lima, L.M.P.; Price, D.W. Metal Complexes of Cyclen and Cyclam Derivatives Useful for Medical Applications: A Discussion Based on Thermodynamic Stability Constants and Structural Data. *Dalt. Trans.* **2007**, 2734–2745. [CrossRef]

17. Paderni, D.; Voccia, M.; Macedi, E.; Formica, M.; Giorgi, L.; Caporaso, L.; Fusi, V. A Combined Solid State, Solution and DFT Study of a Dimethyl-Cyclen-Pd(II) Complex. *Dalt. Trans.* **2024**, 53, 14300–14314. [CrossRef]

18. Verma, A.; Bhuvanesh, N.; Reibenspies, J.; Tayade, S.B.; Kumbhar, A.S.; Bretosh, K.; Sutter, J.P.; Sunkari, S.S. Structurally Characterised New Twisted Conformer for Cyclen, Controlled by Metal Ion Complexation as Seen in NiII and CuII complexes with Halides and Pseudohalides. *CrystEngComm* **2022**, *24*, 119–131. [CrossRef]

19. Harmand, L.; Cadet, S.; Kauffmann, B.; Scarpantonio, L.; Batat, P.; Jonusauskas, G.; McClenaghan, N.D.; Lastécouères, D.; Vincent, J.M. Copper Catalyst Activation Driven by Photoinduced Electron Transfer: A Prototype Photolatent Click Catalyst. *Angew. Chemie-Int. Ed.* **2012**, *51*, 7137–7141. [CrossRef]

20. Zaķis, J.M.; Ozols, K.; Novosjolova, I.; Vilšķērsts, R.; Mishnev, A.; Turks, M. Sulfonyl Group Dance: A Tool for the Synthesis of 6-Azido-2-Sulfonylpurine Derivatives. *J. Org. Chem.* **2020**, *85*, 4753–4771. [CrossRef]

21. Frieden, M.; Aviñó, A.; Eritja, R. Convenient Synthesis of 8-Amino-2'-Deoxyadenosine. *Nucleosides Nucleotides Nucleic Acids* **2003**, *22*, 193–202. [CrossRef]

22. Círule, D.; Novosjolova, I.; Bizdēna, Ē.; Turks, M. 1,2,3-Triazoles as Leaving Groups: S<sub>N</sub>Ar Reactions of 2,6-Bistriazolylpurines with O- And C-Nucleophiles. *Beilstein J. Org. Chem.* **2021**, *17*, 410–419. [CrossRef] [PubMed]

23. Guo, H.M.; Xin, P.Y.; Niu, H.Y.; Wang, D.C.; Jiang, Y.; Qu, G.R. Microwave Irradiated C6-Functionalization of 6-Chloropurine Nucleosides with Various Mild Nucleophiles under Solvent-Free Conditions. *Green Chem.* **2010**, *12*, 2131–2134. [CrossRef]

24. Borrmann, T.; Abdelrahman, A.; Volpini, R.; Lambertucci, C.; Alksnis, E.; Gorzalka, S.; Knospe, M.; Schiedel, A.C.; Cristalli, G.; Müller, C.E. Structure-Activity Relationships of Adenine and Deazaadenine Derivatives as Ligands for Adenine Receptors, a New Purinergic Receptor Family. *J. Med. Chem.* **2009**, *52*, 5974–5989. [CrossRef]

25. Singh, B.; Diaz-Gonzalez, R.; Ceballos-Perez, G.; Rojas-Barros, D.I.; Gunaganti, N.; Gillingwater, K.; Martinez-Martinez, M.S.; Manzano, P.; Navarro, M.; Pollastri, M.P. Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for Trypanosoma Brucei Inhibitors. *J. Med. Chem.* **2020**, *63*, 9912–9927. [CrossRef]

26. Malínková, V.; Řezníčková, E.; Jorda, R.; Gucký, T.; Kryštof, V. Trisubstituted Purine Inhibitors of PDGFRα and Their Antileukemic Activity in the Human Eosinophilic Cell Line EOL-1. *Bioorg. Med. Chem.* **2017**, *25*, 6523–6535. [CrossRef]

27. Novosjolova, I.; Bizdēna, Ē.; Turks, M. Synthesis and Applications of Azolylpurine and Azolylpurine Nucleoside Derivatives. *Eur. J. Org. Chem.* **2015**, *2015*, 3629–3649. [CrossRef]

28. Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.; Hirota, K.; Kawakami, H. Synthesis and Evaluation of 2-Substituted 8-Hydroxyadenines as Potent Interferon Inducers with Improved Oral Bioavailabilities. *Bioorg. Med. Chem.* **2004**, *12*, 1091–1099. [CrossRef]

29. Buchanan, H.S.; Pauff, S.M.; Kosmidis, T.D.; Taladriz-Sender, A.; Rutherford, O.I.; Hatit, M.Z.C.; Fenner, S.; Watson, A.J.B.; Burley, G.A. Modular, Step-Efficient Palladium-Catalyzed Cross-Coupling Strategy to Access C6-Heteroaryl 2-Aminopurine Ribonucleosides. *Org. Lett.* **2017**, *19*, 3759–3762. [CrossRef]

30. Havelková, M.; Dvořák, D.; Hocek, M. The Suzuki-Miyaura Cross-Coupling Reactions of 2-, 6- or 8-Halopurines with Boronic Acids Leading to 2-, 6- or 8-Aryl- and -Alkenylpurine Derivatives. *Synthesis* **2001**, *11*, 1704–1710. [CrossRef]

31. Strouse, J.J.; Ješelnik, M.; Arterburn, J.B. Applications of Boronic Acids in Selective C-C and C-N Arylation of Purines. *Acta Chim. Slov.* **2005**, *52*, 187–199. [CrossRef]

32. Wang, D.C.; Niu, H.Y.; Qu, G.R.; Liang, L.; Wei, X.J.; Zhang, Y.; Guo, H.M. Nickel-Catalyzed Negishi Cross-Couplings of 6-Chloropurines with Organozinc Halides at Room Temperature. *Org. Biomol. Chem.* **2011**, *9*, 7663–7666. [CrossRef] [PubMed]

33. Prasad, A.S.B.; Stevenson, T.M.; Citineni, J.R.; Nyzam, V.; Knochel, P. Preparation and Reactions of New Zincated Nitrogen-Containing Heterocycles. *Tetrahedron* **1997**, *53*, 7237–7254. [CrossRef]

34. Nolsøe, J.M.J.; Gundersen, L.L.; Rise, F. Regiochemistry in the Pd-Mediated Coupling between 6,8-Dihalopurines and Organometallic Reagents. *Acta Chem. Scand.* **1999**, *53*, 366–372.
35. Gundersen, L.L.; Langli, G.; Rise, F. Regioselective Pd-Mediated Coupling between 2,6-Dichloropurines and Organometallic Reagents. *Tetrahedron Lett.* **1995**, *36*, 1945-1948. [CrossRef]

36. Bag, S.S.; Jana, S.; Kasula, M. Sonogashira Cross-Coupling: Alkyne-Modified Nucleosides and Their Applications. In *Palladium-Catalyzed Modification of Nucleosides, Nucleotides and Oligonucleotides*; Kapdi, A.R., Maiti, D., Sanghvi, Y.S., Eds.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 75-146, ISBN 9780128112922.

37. Ibrahim, N.; Chevot, F.; Legraverend, M. Regioselective Sonogashira Cross-Coupling Reactions of 6-Chloro-2,8-diiodo-9-THP-9H-purine with Alkyne Derivatives. *Tetrahedron Lett.* **2011**, *52*, 305-307.

38. Bilbao, N.; Vázquez-González, V.; Aranda, M.T.; González-Rodríguez, D. Synthesis of 5-/8-Halogenated or Ethynylated Lipophilic Nucleobases as Potential Synthetic Intermediates for Supramolecular Chemistry. *Eur. J. Org. Chem.* **2015**, *2015*, 7160-7175. [CrossRef]

39. Hocek, M.; Pohl, R. Regioselectivity in Cross-Coupling Reactions of 2,6,8-Trichloro-9-(Tetrahydropyran-2-yl)Purine: Synthesis of 2,6,8-Trisubstituted Purine Bases. *Synthesis* **2004**, *36*, 2869-2876. [CrossRef]

40. Hocek, M.; Hocková, D.; Dvořáková, H. Dichotomy in Regioselective Cross-Coupling Reactions of 6,8-Dichloropurines with Phenylboronic Acid and Methylmagnesium Chloride: Synthesis of 6,8-Di-Substituted Purines. *Synthesis* **2004**, *6*, 889-894. [CrossRef]

41. Mahajan, T.R.; Ytre-Arne, M.E.; Strøm-Andersen, P.; Dalhus, B.; Gundersen, L.L. Synthetic Routes to N-9 Alkylated 8-Oxoguanines; Weak Inhibitors of the Human DNA Glycosylase OGG1. *Molecules* **2015**, *20*, 15944-15965. [CrossRef]

42. Abdoli, M.; Mirjafary, Z.; Saeidian, H.; Kakanejadifard, A. New Developments in Direct Functionalization of C-H and N-H Bonds of Purine Bases via Metal Catalyzed Cross-Coupling Reactions. *RSC Adv.* **2015**, *5*, 44371-44389. [CrossRef]

43. Mooney, D.T.; Moore, P.R.; Lee, A.L. Direct Minisci-Type C-H Amidation of Purine Bases. *Org. Lett.* **2022**, *24*, 8008-8013. [CrossRef] [PubMed]

44. Larsen, A.F.; Ulven, T. Direct N9-Arylation of Purines with Aryl Halide. *Chem. Commun.* **2014**, *50*, 4997-4999. [CrossRef]

45. Chen, S.; Graceffa, R.F.; Boezio, A.A. Direct, Regioselective N-Alkylation of 1,3-Azoles. *Org. Lett.* **2016**, *18*, 16-19. [CrossRef]

46. Tranová, L.; Stýskala, J. Study of the N7 Regioselective Glycosylation of 6-Chloropurine and 2,6-Dichloropurine with Tin and Titanium Tetrachloride. *J. Org. Chem.* **2021**, *86*, 13265-13275. [CrossRef]

47. Nevrlka, F.; Bědroň, A.; Valenta, M.; Tranová, L.; Stýskala, J. Study of Direct N⁷ Regioselective Tert-Alkylation of 6-Substituted Purines and Their Modification at Position C6 through O, S, N, and C Substituents. *ACS Omega* **2024**, *9*, 17368-17378. [CrossRef]

48. Sebris, A.; Novosjolova, I.; Turks, M. Synthesis of 7-Arylpurines from Substituted Pyrimidines. *Synthesis* **2022**, *54*, 5529-5539. [CrossRef]

49. Bollier, M.; Klipsch, F.; Six, P.; Dubuquoy, L.; Azaroual, N.; Millet, R.; Leleu-Chavain, N. One- or Two-Step Synthesis of C-8 and N-9 Substituted Purines. *J. Org. Chem.* **2018**, *83*, 422-430. [CrossRef]

50. Dasari, S.; Bernard Tchounwou, P. Cisplatin in Cancer Therapy: Molecular Mechanisms of Action. *Eur. J. Pharmacol.* **2014**, *740*, 364-378. [CrossRef]

51. Taqui Khan, M.; Krishnamoorthy, C.R. Interaction of Metal Ions with Monosubstituted Purines. *J. Inorg. Nucl. Chem.* **1971**, *33*, 1417-1425. [CrossRef]

52. Gao, S.H.; Xie, M.S.; Wang, H.X.; Niu, H.Y.; Qu, G.R.; Guo, H.M. Highly Selective Detection of Hg²⁺ Ion by Push-Pull-Type Purine Nucleoside-Based Fluorescent Sensor. *Tetrahedron* **2014**, *70*, 4929-4933. [CrossRef]

53. Li, J.P.; Wang, H.X.; Wang, H.X.; Xie, M.S.; Qu, G.R.; Niu, H.Y.; Guo, H.M. Push-Pull-Type Purine Nucleoside-Based Fluorescent Sensors for the Selective Detection of Pd²⁺ in Aqueous Buffer. *Eur. J. Org. Chem.* **2014**, *2014*, 2225-2230. [CrossRef]

54. Chen, X.; Mao, Y.; Wang, A.; Lu, L.; Shao, Q.; Jiang, C.; Lu, H. Synthesis and Application of Purine-Based Fluorescence Probe for Continuous Recognition of Cu²⁺ and Glyphosate. *Spectrochim. Acta-Part A Mol. Biomol. Spectrosc.* **2024**, *304*, 123291. [CrossRef]

55. Tao, X.; Mao, Y.; Alam, S.; Wang, A.; Qi, X.; Zheng, S.; Jiang, C.; Chen, S.Y.; Lu, H. Sensitive Fluorescence Detection of Glyphosate and Glufosinate Ammonium Pesticides by Purine-Hydrazone-Cu²⁺ Complex. *Spectrochim. Acta-Part A Mol. Biomol. Spectrosc.* **2024**, *314*, 124226. [CrossRef]

56. Sadowska, P.; Jankowski, W.; Bregier-Jarzębowska, R.; Pietrzyk, P.; Jastrząb, R. Deciphering the Impact of Nucleosides and Nucleotides on Copper Ion and Dopamine Coordination Dynamics. *Int. J. Mol. Sci.* **2024**, *25*, 9137. [CrossRef]

57. Schino, I.; Cantore, M.; de Candia, M.; Altomare, C.D.; Maria, C.; Barros, J.; Cachatra, V.; Calado, P.; Shimizu, K.; Freitas, A.A.; et al. Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer's Disease. *Pharmaceuticals* **2023**, *16*, 54. [CrossRef]

58. Xu, H.; Chen, W.; Ju, L.; Lu, H. A Purine Based Fluorescent Chemosensor for the Selective and Sole Detection of Al³⁺ and Its Practical Applications in Test Strips and Bio-Imaging. *Spectrochim. Acta-Part A Mol. Biomol. Spectrosc.* **2021**, *247*, 119074. [CrossRef]

59. Jovaisaite, J.; Cīrule, D.; Jeminejs, A.; Novosjolova, I.; Turks, M.; Baronas, P.; Komskis, R.; Tumkevicius, S.; Jonusauskas, G.; Jursenas, S. Proof of Principle of a Purine D-A-D' Ligand Based Ratiometric Chemical Sensor Harnessing Complexation Induced Intermolecular PET. *Phys. Chem. Chem. Phys.* **2020**, *22*, 26502-26508. [CrossRef]
60. Tomczyk, M.D.; Kuźnik, N.; Walczak, K. Cyclen-Based Artificial Nucleases: Three Decades of Development (1989–2022). Part a–Hydrolysis of Phosphate Esters. *Coord. Chem. Rev.* **2023**, *481*, 215047. [CrossRef]

61. Gałęzowska, J.; Boratyński, P.J.; Kowalczyk, R.; Lipke, K.; Czapor-Irzabek, H. Copper(II) Complexes of Chiral 1,2,3-Triazole Biheterocyclic 'Click' Ligands Equipped in Cinchona Alkaloid Moiety. *Polyhedron* **2017**, *121*, 1–8. [CrossRef]

62. Cheney, G.E.; Freiser, H.; Fernando, Q.; Freiser, H. Metal Complexes of Purine and Some of Its Derivatives. *J. Am. Chem. Soc.* **1959**, *81*, 2611–2615. [CrossRef]

63. Petrenko, Y.P.; Piasta, K.; Khomenko, D.M.; Doroshchuk, R.O.; Shova, S.; Novitchi, G.; Toporivska, Y.; Gumienna-Kontecka, E.; Martins, L.M.D.R.S.; Lampeka, R.D. An Investigation of Two Copper(II) Complexes with a Triazole Derivative as a Ligand: Magnetic and Catalytic Properties. *RSC Adv.* **2021**, *11*, 23442–23449. [CrossRef] [PubMed]

64. Pérez-Toro, I.; Domínguez-Martín, A.; Choquesillo-Lazarte, D.; Vílchez-Rodríguez, E.; González-Pérez, J.M.; Castiñeiras, A.; Niclós-Gutiérrez, J. Lights and Shadows in the Challenge of Binding Acyclovir, a Synthetic Purine-like Nucleoside with Antiviral Activity, at an Apical-Distal Coordination Site in Copper(II)-Polyamine Chelates. *J. Inorg. Biochem.* **2015**, *148*, 84–92. [CrossRef] [PubMed]

65. Rahman, M.S.; Yuan, H.Q.; Kikuchi, T.; Fujisawa, I.; Aoki, K. Metal Ion Interactions with Nucleobases in the Tetradentate 1,4,7,10-Tetraazacyclododecane (Cyclen)-Ligand System: Crystal Structures of [Cu(Cyclen)(Adeninato)]·ClO₄·2H₂O, [[Cu(Cyclen)]₂(Hypoxanthinato)]·(ClO₄)₃, [Cu(Cyclen)(Theophyllinato)]₃·(ClO₄)₃·2H₂O, and [Cu(cyclen)(theophyllinato)]₃·(ClO₄)₃·2H₂O, and [Cu(cyclen)(xanthinato)]·(0.7ClO₄)₃·(0.3ClO₄)₃·3H₂O·(0.5H₂O)₃. *J. Mol. Struct.* **2010**, *966*, 92–101. [CrossRef]

66. Šišulins, A.; Bucevičius, J.; Tseng, Y.T.; Novosjolova, I.; Traskovskis, K.; Bizdēna, Ē.; Chang, H.T.; Turnkevičius, S.; Turks, M. Synthesis and Fluorescent Properties of N(9)-Alkylated 2-Amino-6-Triazolylpurines and 7-Deazapurines. *Beilstein J. Org. Chem.* **2019**, *15*, 474–489. [CrossRef]

67. Sebris, A.; Traskovskis, K.; Novosjolova, I.; Turks, M. Synthesis and Photophysical Properties of 2-Azolyl-6-Piperidinylpurines. *Chem. Heterocycl. Compd.* **2021**, *57*, 560–567. [CrossRef]

68. Sessler, J.L.; Sathiosatham, M.; Doerr, K.; Lynch, V.V.; Abboud, K.A. A G-Quartet Formed in the Absence of a Templating Metal Cation: A New 8-(N,N-Dimethylaniline)Guanosine Derivative. *Angew. Chem. Int. Ed. Engl.* **2000**, *39*, 1300–1303. [CrossRef]

69. Liu, T.; Zhan, W.; Wang, Y.; Zhang, L.; Yang, B.; Dong, X.; Hu, Y. Structure-Based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives as Novel Akt1 Inhibitors. *Eur. J. Med. Chem.* **2014**, *73*, 167–176. [CrossRef]

70. Selmani, A.; Serpier, F.; Darses, S. From Tetrahydrofurans to Tetrahydrobenzo[d]Oxepines via a Regioselective Control of Alkyne Insertion in Rhodium-Catalyzed Arylative Cyclization. *J. Org. Chem.* **2019**, *84*, 4566–4574. [CrossRef]

71. Zhao, D.; Wu, N.; Zhang, S.; Xi, P.; Su, X.; Lan, J.; You, J. Synthesis of Phenol, Aromatic Ether, and Benzofuran Derivatives by Copper-Catalyzed Hydroxylation of Aryl Halides. *Angew. Chemie-Int. Ed.* **2009**, *48*, 8729–8732. [CrossRef]

72. Altman, R.A.; Shafir, A.; Choi, A.; Lichtor, P.A.; Buchwald, S.L. An Improved Cu-Based Catalyst System for the Reactions of Alcohols with Aryl Halides. *J. Org. Chem.* **2008**, *73*, 284–286. [CrossRef]

73. Niu, J.; Guo, P.; Kang, J.; Li, Z.; Xu, J.; Hu, S. Copper(I)-Catalyzed Aryl Bromides to Form Intermolecular and Intramolecular Carbon-Oxygen Bonds. *J. Org. Chem.* **2009**, *74*, 5075–5078. [CrossRef] [PubMed]

74. Kreibich, M.; Petrović, D.; Brückner, R. Mechanistic Studies of the Deslongchamps Annulation. *J. Org. Chem.* **2018**, *83*, 1116–1133. [CrossRef] [PubMed]

75. Ohashi, M.; Konkol, M.; Del Rosal, I.; Poteau, R.; Maron, L.; Okuda, J. Rare-Earth Metal Alkyl and Hydride Complexes Stabilized by a Cyclen-Derived [NNNN] Macro cyclic Ancillary Ligand. *J. Am. Chem. Soc.* **2008**, *130*, 6920–6921. [CrossRef]

76. Mereshchenko, A.S.; Olshin, P.K.; Karimov, A.M.; Skripkin, M.Y.; Burkov, K.A.; Tveryanovich, Y.S.; Tarnovsky, A.N. Photochemistry of Copper(II) Chlorocomplexes in Acetonitrile: Trapping the Ligand-to-Metal Charge Transfer Excited Staterelaxations Pathways. *Chem. Phys. Lett.* **2014**, *615*, 105–110. [CrossRef]

77. Ding, H.W.; Wang, S.; Qin, X.C.; Wang, J.; Song, H.R.; Zhao, Q.C.; Song, S.J. Design, Synthesis, and Biological Evaluation of Some Novel 4-Aminoquinazolines as Pan-PI3K Inhibitors. *Bioorg. Med. Chem.* **2019**, *27*, 2729–2740. [CrossRef]

78. Qiu, X.P.; Korchagina, E.V.; Rolland, J.; Winnik, F.M. Synthesis of a Poly(N-Isopropylacrylamide) Charm Bracelet Decorated with a Photomobile α-Cyclodextrin Charm. *Polym. Chem.* **2014**, *5*, 3656–3665. [CrossRef]

79. Mazaki, Y.; Mutai, K. Charge-Transfer Interaction and Molecular Arrangement in the Crystals of 2-(p-Nitrophenoxy)Ethyl Ethers and Amines. *Bull. Chem. Soc. Jpn.* **1995**, *68*, 3247–3254. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.